Across eight conversations, one theme kept surfacing in Phil Blackmore’s latest What If? series: pharma doesn’t have a relevance problem because people don’t care about healthcare. It has a relevance problem because too much of the industry still operates around structures, metrics and behaviours that no longer reflect how…

In a recent conversation, Phil sat down with Cormac Wooller and Eleanor Dance from Bayer to talk about how they’ve found their way into the industry and what they’re learning from the inside. Previously a Carpenter by trade, Cormac joined Bayer over five years ago as a Digital Marketing…

In 2022, the UK Government published the Women’s Health Strategy for England, the first government-led strategy of its kind focused on the health experiences of women and girls. Its opening statement was to the point: “Women have told us that they are not listened to. They feel that their voices…

There’s a quiet assumption in our industry that good thinking just… happens. In the gaps between meetings, across endless email threads, within the safety of familiar teams. In pharma especially, thinking often happens in lanes. Medical refines the science. Marketing shapes the story. Market access builds the case. The…

There’s a stat in our latest Fabric of Pharma report that stops people mid-sentence: 70% of Gen Z healthcare professionals surveyed feel they can’t trust pharmaceutical companies. Not “are sceptical.” Not “need more information.” Can’t trust. For an industry built on evidence, outcomes and partnerships, this isn’t just uncomfortable,…

According to recent research by Cancer Research, the NHS is well below its targets for the time between diagnosis of cancer and first treatment. Only 68.8% of people in England received diagnosis and started treatment within the 2 months (or 62 days) standard. Even more worryingly, the target of…

Much progress is being made in the treatment of Parkinson’s Disease. From novel oral medications to new drug delivery systems, advances in surgical techniques, and promising clinical trials of stem cell therapies.  The prospects and prognosis for the average Parkison’s patient could look dramatically different within the next 5-10…

On LinkedIn, every other post is about AI, as it has been for many months. Perhaps it’s an AI-generated video clip that will ‘blow your mind’. Perhaps it’s a post about how copywriters can (or cannot) safeguard their role from the threat of AI. Perhaps it’s hacks for using…

At Create Health, we pride ourselves on combining scientific depth with creative brilliance to deliver meaningful healthcare communications that resonate — whether we’re engaging specialist HCPs, informing patients, or driving adoption of life-changing innovations. While we partner with brands across a wide range of therapy areas, there are a…

The migraine market, on the surface, seems relatively well-served. It’s considered fast-moving, with a sizeable pipeline of treatments, including drugs with novel pharmaceutical mechanisms, and non-pharmacological treatments too. The EU migraine market was worth 3.8bn as of 2023, and it’s predicted to continue to grow. Pharmaceutical treatment is currently…